Highlights

• Chimeric Therapeutics Company: Chimeric Therapeutics Limited | ASX code: CHM Verified index: None verified (index omitted; ASX-listed) Publication.

• Chimeric Therapeutics is rethinking its cancer cell therapy strategy because safety limits in its CDH17 CAR-T trial stopped.

• At the third dose level, 450 million CAR-T cells, the second patient had Grade 3 adverse events: a.

• The company reports anti-tumour activity in all 14 patients treated, including complete reduction of some target lesions, with.

Chimeric Therapeutics (ASX:CHM) — Company: Chimeric Therapeutics Limited | ASX code: CHM Verified index: None verified (index omitted; ASX-listed) Publication date: 2026-10-29 Data cut-off: Company announcement of 19 August 2026; index check against S&P Dow Jones Indices ASX 200 announcement of 4 September 2026 Body word count: 600

The short answer

Chimeric Therapeutics is rethinking its cancer cell therapy strategy because safety limits in its CDH17 CAR-T trial stopped further dosing. On 19 August 2026 the company ceased enrolment in its Phase 1/2 trial of CHM-2101 and said that product will not progress in its current form. It is now looking to an in vivo approach, while it also seeks funding. It is ASX-listed, but this article could not confirm membership of any ASX index.

What happened in the trial

CHM-2101 is an autologous CDH17 CAR-T therapy being tested in advanced colorectal cancer, gastric cancer and intestinal neuroendocrine tumours.

At the third dose level, 450 million CAR-T cells, the second patient had Grade 3 adverse events: a gastrointestinal fistula, rectal pain and a pelvic infection. The independent Safety Monitoring Committee judged these probably related to CHM-2101 and a dose-limiting toxicity, the second among four patients at that dose. It concluded the dose was unsafe and that the protocol's stopping trigger had been met. The company has already notified the US Food and Drug Administration.

What the data showed

The company reports anti-tumour activity in all 14 patients treated, including complete reduction of some target lesions, with CAR-T cells persisting for up to 15 months and no new tumours evident. It concludes that CDH17 is a valid target, but that the doses needed for activity were not tolerated with the current autologous product.

Existing patients will continue follow-up, mainly through an external contract research organisation. Any restart would require a protocol amendment, regulatory and ethics approvals, and might involve intermediate doses or changed eligibility criteria.

The new direction

The company is now focusing on an in vivo CDH17 CAR, in which the CAR construct is delivered directly to the patient rather than built from the patient's own cells. This work is preclinical and no development candidate has been selected. The existing University of Pennsylvania licence covers in vivo development, so no new licence is needed. Animal feasibility work is expected to begin in the coming months, subject to additional funding.

Costs, funding and going concern

Chimeric has cut headcount, manufacturing and trial-related costs, which it estimates will save about A$4 million a year after initial termination costs. A process to sell, out-licence or partner the CDH17 asset drew no current interest from pharmaceutical companies and was due to close on 31 August 2026.

Funding discussions are incomplete, and no binding commitment has been received. An entitlement offer is being considered, and some funding may need shareholder approval. The company also plans to negotiate with creditors, including the provider of its convertible facility, to reduce liabilities. It expects its financial report for the year to 30 June 2026 to include a material uncertainty about going concern, and said the Appendix 4E would be released without an audit opinion while the audit was still in progress.

Sector context

Cell therapy for solid tumours is difficult. Targets must be present on tumour cells and absent or limited on healthy tissue, and doses that work can cause damaging side effects. Chimeric's experience shows how narrow that window can be.

Risks and uncertainties

The central risks are financial and scientific. Without new funding the company may not be able to carry out its plans. An in vivo programme without a selected candidate is years from patients. Creditor negotiations and any entitlement offer could change the position of existing holders, and the outcome is uncertain.

What to watch

Useful signals include the filing of the audited annual report, any funding announcement, outcomes of the strategic review, and the planned meetings with clinical advisers. The company also promised a further shareholder update after its Board review. Readers should rely on the original ASX announcement of 19 August 2026 rather than this summary.